Endocrine Abstracts

Introduction: Flash glucose monitoring has been widely used for people with T1DM over the last 10 years. In March 2022 NICE guidelines recommended extending use to people with T2DM on insulin, previously use was limited to people on dialysis and those self-funding.

Aim: To examine the use and outcomes of flash glucose monitoring in people with T2DM.

Methods: People with T2DM locally who have used flash glucose monitoring for more than 90 days were identified on Libreview®. We used hospital records to identify HbA1c prior to initiation and at least 60 days post initiation. Sensor data were evaluated using Libreview.

Results: Using LibreView, we identified 25 people with T2DM, mean age 57.9 (± 10.53) who used flash monitoring for > 90 days between March 2021 and April 2022. All patients were on insulin, 14 were on basal-bolus, 4 on mixed insulin and 7 on basal only. 6 were on injectable GLP-1 agonists and 8 were on oral hypoglycaemic medications. 7 people were on haemodialysis and 3 were post renal transplant. We have pre and post HbA1c for 18 people. The median HbA1c reduction was 0.45% (4.9 mmol/l) (IQR -1.5% to +0.26%). The median Time In Range (TIR) was 63% (range 0% - 96%), with 32% having TIR over 70%. Median Time Below Range was 0% (range 0% - 6%), median Time Above Range was 37% (range 1% - 100%). Mean GMI was 7.87 (± 1.64).

Conclusions: Flash glucose monitoring has similar reductions in HbA1c in T2DM as in T1DM. Wider use as per newer NICE guidance will help a wider population of people with insulin treated diabetes.